A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
Details
Age
Adult
Locations
Highlands Ranch Hospital
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Jessica McDermott
Study ID
Protocol Number: 23-2332
More information available at ClinicalTrials.gov: NCT06129864
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers